Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis.
The anticonvulsant effects produced by stiripentol (STP), carbamazepine (CBZ), and their combination in the maximal electroshock (MES)-induced seizures in mice were investigated using three-dimensional (3D) isobolographic analysis. With 3D isobolography, the combinations of both drugs at the fixed-ratios of 1:3, 1:1, and 3:1 for 16%, 50% and 84% antiseizure effects, respectively, were examined in order to evaluate the preclinical characteristics of the interactions between STP and CBZ. Additionally, to characterize precisely the types of interactions observed in the MES test, free plasma and total brain CBZ concentrations were estimated for all fixed-ratios tested. The 3D isobolographic analysis showed that STP and CBZ combined at the fixed-ratio of 1:3 produced supra-additive (synergistic) interactions in the MES test for the anticonvulsant effects ranging between 16% and 84%. In contrast, the combination of STP with CBZ at the fixed-ratio of 3:1 exerted sub-additive (antagonistic) interactions in 3D isobolography for all antiseizure effects examined in the MES test. Only the combination of STP and CBZ at the fixed-ratio of 1:1 was additive for the investigated effects (16%, 50% and 84%) in 3D isobolography. Pharmacokinetic evaluation of CBZ concentrations revealed that STP increased both free plasma and total brain CBZ concentrations for all fixed-ratio combinations tested (1:3, 1:1 and 3:1). In conclusion, the 3D isobolographic findings suggest that the combination of STP with CBZ exerted biphasic characteristics of interactions in the MES test, despite the pharmacokinetic increase in CBZ content in plasma and brains of experimental animals.
Luszczki
Jarogniew J
JJ
Department of Pathophysiology, Medical University of Lublin, Jaczewskiego 8, 20-090 Lublin, Poland. jarogniew.luszczki@am.lublin.pl
Czuczwar
Stanislaw J
SJ
D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D001921:Brain / Q000378:metabolism; D002220:Carbamazepine / Q000493:pharmacokinetics / Q000494:pharmacology*; D004148:Dioxolanes / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004597:Electroshock; D008297:Male; D051379:Mice; D012640:Seizures / Q000188:drug therapy*
D000927:Anticonvulsants; D004148:Dioxolanes; D002220:Carbamazepine; C021092:stiripentol